Lawmakers say warning letter appeals process should be reviewed
This article was originally published in The Silver Sheet
FDA needs to review its enforcement dispute resolution process, two leading Republicans on the House Energy and Commerce Committee say. In a Nov. 14 letter, Joe Barton, R-Texas, and Ed Whitfield, R-Ky., ask FDA Commissioner Andrew von Eschenbach to "personally review how center directors monitor top disputes and controversies, and report back on management performance in this area and whether any further steps or actions will be taken to improve dispute resolution and priority setting of enforcement resources." Barton, the ranking Republican of the full committee, and Whitfield, the ranking member of the subcommittee on oversight and investigations, first inquired into FDA's warning letter appeals process in an April letter to von Eschenbach in response to the agency's actions against Colorado dental implant company TMJ Implants ("The Silver Sheet" May 2007)
You may also be interested in...
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.